Abstract | INTRODUCTION: AREAS COVERED: We summarize recent patent activity regarding PPARγ ligands and their therapeutic applications from 2008. Pharmacologic methods to increase PPARγ expression and to decrease PPARγ adverse effects by combining PPARγ ligands with other drugs are also reviewed. EXPERT OPINION: In addition to novel PPARγ ligands that exhibit selective therapeutic activity without adverse effects, such as bone loss, fluid retention or weight gain, methods for the combination of PPARγ ligands and other compounds have been claimed to decrease adverse effects and/or to enhance targeted effects. Combination therapy is useful but has the potential risk of unexpected adverse effects. Patent applications for expanding clinical application of PPARγ ligands to non- metabolic diseases, such as neurological and inflammatory diseases, and to skin whitening have been filed, and future studies are needed to elucidate the underlying mechanisms.
|
Authors | Ichiro Takada, Makoto Makishima |
Journal | Expert opinion on therapeutic patents
(Expert Opin Ther Pat)
Vol. 25
Issue 2
Pg. 175-91
(Feb 2015)
ISSN: 1744-7674 [Electronic] England |
PMID | 25416646
(Publication Type: Journal Article, Research Support, Non-U.S. Gov't, Review)
|
Chemical References |
- Hypoglycemic Agents
- Ligands
- PPAR gamma
- Thiazolidinediones
|
Topics |
- Animals
- Diabetes Mellitus, Type 2
(drug therapy)
- Drug Design
- Humans
- Hypoglycemic Agents
(adverse effects, pharmacology)
- Ligands
- Lipid Metabolism
- PPAR gamma
(drug effects, metabolism)
- Patents as Topic
- Thiazolidinediones
(adverse effects, pharmacology)
|